Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy pipeline landscape. It covers the Fuchs Endothelial Corneal Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Fuchs Endothelial Corneal Dystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Fuchs Endothelial Corneal Dystrophy Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/fuchs-endothelial-corneal-dystrophy-pipeline-insight
Key Takeaways from the Fuchs Endothelial Corneal Dystrophy Pipeline Report
- In December 2025, Design Therapeutics Inc. announced a phase 2, Multicenter, Open-Label Study to assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty.
- In November 2025, Kowa Research Institute Inc. conducted a Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy.
- DelveInsight’s Fuchs Endothelial Corneal Dystrophy Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Fuchs Endothelial Corneal Dystrophy treatment.
- The leading Fuchs Endothelial Corneal Dystrophy Companies, such as Trefoil Therapeutics, Kowa Pharmaceutical, Santen Pharmaceutical and others.
- Promising Fuchs Endothelial Corneal Dystrophy Therapies such as DT-168, Netarsudil Ophthalmic Solution, Ripasudil, STN1010904 ophthalmic suspension 0.03% BID, K-321 Solution, TTHX1114(NM141), Prednisolone acetate, Fluorometholone and others.
Want to know which companies are leading innovation in Fuchs Endothelial Corneal Dystrophy? Dive into the full pipeline insights @ Fuchs Endothelial Corneal Dystrophy Clinical Trials Assessment
The Fuchs Endothelial Corneal Dystrophy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Fuchs Endothelial Corneal Dystrophy Pipeline Report also highlights the unmet needs with respect to the Fuchs Endothelial Corneal Dystrophy.
Fuchs Endothelial Corneal Dystrophy Overview
Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive, inherited eye disorder that affects the corneal endothelium, the innermost layer of the cornea responsible for maintaining corneal clarity. The disease is characterized by the gradual loss of endothelial cells, leading to impaired fluid regulation within the cornea and resulting in corneal swelling (edema) and vision deterioration over time.
Fuchs Endothelial Corneal Dystrophy Emerging Drugs Profile
- TTHX 1114: Trefoil Therapeutics
TTHX1114 is a proprietary, engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which naturally functions to stimulate cell proliferation and migration as well as protect cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s pharmacodynamic half-life, enabling its use as a pharmaceutical. TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer. In addition to the trial in patients undergoing DSO surgery, the company is conducting a Phase 1/2 trial (“INTREPID”) to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to corneal endothelial disorders, including FECD.
- Ripasudil hydrocholoride hydrate: Kowa Pharmaceutical
Ripasudil hydrochloride hydrate is a rho-kinase inhibitor, it has been suggested that the compound may also act on other kinases in the eye, leading to investigations of its applicability to other ophthalmic diseases. As part of these efforts, development of the compound as a treatment for Fuchs endothelial corneal dystrophy (FECD) is underway.
If you’re tracking ongoing Fuchs Endothelial Corneal Dystrophy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Fuchs Endothelial Corneal Dystrophy Treatment Drugs
The Fuchs Endothelial Corneal Dystrophy Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Fuchs Endothelial Corneal Dystrophy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fuchs Endothelial Corneal Dystrophy Treatment.
- Fuchs Endothelial Corneal Dystrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Fuchs Endothelial Corneal Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fuchs Endothelial Corneal Dystrophy market.
Fuchs Endothelial Corneal Dystrophy Companies
Trefoil Therapeutics, Kowa Pharmaceutical, Santen Pharmaceutical and others.
Fuchs Endothelial Corneal Dystrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Fuchs Endothelial Corneal Dystrophy Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
From emerging drug candidates to competitive intelligence, the Fuchs Endothelial Corneal Dystrophy Pipeline Report covers it all – check it out now @ Fuchs Endothelial Corneal Dystrophy Market Drivers and Barriers, and Future Perspectives
Scope of the Fuchs Endothelial Corneal Dystrophy Pipeline Report
- Coverage- Global
- Fuchs Endothelial Corneal Dystrophy Companies- Trefoil Therapeutics, Kowa Pharmaceutical, Santen Pharmaceutical and others.
- Fuchs Endothelial Corneal Dystrophy Therapies- DT-168, Netarsudil Ophthalmic Solution, Ripasudil, STN1010904 ophthalmic suspension 0.03% BID, K-321 Solution, TTHX1114(NM141), Prednisolone acetate, Fluorometholone and others.
- Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Fuchs Endothelial Corneal Dystrophy Treatment landscape in this detailed analysis @ Fuchs Endothelial Corneal Dystrophy Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Fuchs Endothelial Corneal Dystrophy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Fuchs Endothelial Corneal Dystrophy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- TTHX 1114: Trefoil Therapeutics
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Fuchs Endothelial Corneal Dystrophy Key Companies
- Fuchs Endothelial Corneal Dystrophy Key Products
- Fuchs Endothelial Corneal Dystrophy- Unmet Needs
- Fuchs Endothelial Corneal Dystrophy- Market Drivers and Barriers
- Fuchs Endothelial Corneal Dystrophy- Future Perspectives and Conclusion
- Fuchs Endothelial Corneal Dystrophy Analyst Views
- Fuchs Endothelial Corneal Dystrophy Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-pipeline-insight
